Abstract:Objectives Early placement of transjugular intrahepatic portosystemic shunt (TIPS) has been shown to improve survival in high-risk patients (Child-Pugh B plus active bleeding at endoscopy or Child-Pugh C 10-13) with cirrhosis and acute variceal bleeding (AVB). However, early TIPS criteria may overestimate the mortality risk in a significant proportion of patients, and the survival benefit conferred by early TIPS in such patients has been questioned. Alternative criteria have been proposed to refine the criteria used to identify candidates for early TIPS. Nevertheless, the true survival benefit provided (or not) by early TIPS compared with standard treatment in the different risk categories has not been investigated in specifically designed comparative studies. Design We collected data on 1425 consecutive patients with cirrhosis and AVB who were admitted to 12 university hospitals in China between December 2010 and June 2016. Of these, 206 patients received early TIPS, and 1219 patients received standard treatment. The Fine and Gray competing risk regression model was used to compare the outcomes between the two groups that were stratified based on the currently available risk stratification systems after adjusting for liver disease severity and other potential confounders. Results Overall, early TIPS was associated with an 80% relative risk reduction (RRR) in mortality at 6 weeks (adjusted HR=0.20; 95% CI : 0.10 to 044; p<0.001) and 51% RRR at 1 year (adjusted HR=0.49, 95% CI : 0.32 to 0.73; p<0.001) compared with standard treatment. In stratification analyses, the RRRs in mortality did not significantly differ among the risk categories. However, the absolute risk reductions (ARRs) of mortality were more pronounced in high-risk patients. The ARRs at 6 weeks were -2.1%, -10.2% and -32.4% in Model for End-stage Liver Disease (MELD) <= 11, 12-18 and >= 19 patients and were -1.5%, -9.1% and -23.2% in Child-Pugh A, B and C patients, respectively (interaction tests, p<0.001 for both criteria). The ARRs for mortality at 1 year were -1.7%, -5.4% and -32.7% in MELD <= 11, 12-18 and >= 19 patients, respectively, and -3.6%, -5.2% and -20.3% in Child-Pugh A, B and C patients, respectively (interaction tests, p<0.001 for both criteria). After adjusting for liver disease severity and other potential confounders, a survival benefit was observed in MELD >= 19 or Child-Pugh C patients but not in MELD <= 11 or Child-Pugh A patients. In MELD 12-18 patients, a survival benefit was observed within 6 weeks but not at 1 year. In Child-Pugh B patients, a survival benefit was observed in those with active bleeding but not those without active bleeding. However, the evaluation of active bleeding was associated with a high interobserver variability. Furthermore, early TIPS was associated with a significantly reduced incidence of failure to control bleeding or rebleeding and new or worsening ascites, without increasing the risk of overt hepatic encephalopathy. Conclusions Early TIPS was associated with improved survival in patients with MELD >= 19 or Child-Pugh C cirrhosis but not in patients with MELD <= 11 or Child-Pugh A cirrhosis. For MELD 12-18 or ChildPugh B patients, future studies addressing optimal selection criteria for early TIPS remain highly warranted.

Letter: Prospective evaluation of patients with non‐cirrhotic portal hypertension: A single‐centre study

Letter: Prospective evaluation of patients with non‐cirrhotic portal hypertension—A single centre study. Authors' reply

Prospective evaluation of patients with non‐cirrhotic portal hypertension: A single centre study

Identifying Optimal Candidates for Early TIPS among Patients with Cirrhosis and Acute Variceal Bleeding: a Multicentre Observational Study

Porto-sinusoidal vascular liver disorder with portal hypertension: Natural History and Long-Term Outcome.

The portal hypertension syndrome: etiology, classification, relevance, and animal models

Letter: Helicobacter pylori and metabolic syndrome‐related von Willebrand factor and plasminogen activator inhibitor‐1 activity levels for outcome prediction of advanced chronic liver disease

Incidence, predictive factors and clinical significance of development of portal vein thrombosis in cirrhosis: A prospective study

Regression of portal hypertension: underlying mechanisms and therapeutic strategies

Invasive and Non-invasive Diagnosis of Portal Hypertension in Cirrhosis

Bibliometric-analysis visualization and review of non-invasive methods for monitoring and managing the portal hypertension

The Impact of Portal Hypertension Assessment Method on the Outcomes of Hepatocellular Carcinoma Resection: A Meta-Analysis of Matched Cohort and Prospective Studies

Noncontrast-enhanced MRI-based Noninvasive Score for Portal Hypertension (CHESS1802): an International Multicenter Study

Non-invasive liver disease assessment to identify portal hypertension: A systematic review supporting the AASLD Practice Guideline

A multicentre, multinational study of clinical characteristics and prognosis of hepatocellular carcinoma

Efficacy and Safety of Treatments for Patients with Portal Hypertension and Cirrhosis: A Systematic Review and Bayesian Network Meta-Analysis

Impact of Losartan on Portal hypertension and Liver Cirrhosis: A Systematic Review

Laparoscopic Liver Resection for Hepatocellular Carcinoma in Child-Pugh A Patients With and Without Portal Hypertension: A Multicentre Study

Letter: Risks of proton pump inhibitor treatment in cirrhotic patients—Authors' reply

Evaluation of portal hypertension in the cirrhotic patient: hepatic vein pressure gradient and beyond

The role of 2D-Shearwave elastography in non invasive portal hypertension diagnosis